Federal Jury Rules Against Avilar Therapeutics in Trade Secret Case Involving Yale and Biohaven

Federal Jury Rules Against Avilar Therapeutics in Trade Secret Case

In a significant legal battle, a federal jury in Delaware ruled in favor of Biohaven Ltd. and Yale University, awarding a total of $4 million in damages after determining that Avilar Therapeutics and RA Capital maliciously misappropriated trade secrets. This verdict came after a trial highlighting the serious nature of trade secret theft and the critical importance of legal protections around intellectual property.

The controversy stemmed from a technology developed by Dr. David Spiegel at Yale University known as the "MODA" targeted protein degradation platform. This innovative technology is intended to remove harmful extracellular proteins from the body, potentially leading to breakthroughs in treating various diseases. Dr. Spiegel had presented his work during Yale's Lifesciences Pitchfest in 2018, which attracted interest from various investment firms.

In April 2019, RA Capital entered into a confidentiality agreement with Yale to explore a partnership regarding the MODA platform. However, after months of negotiations and an exchange of confidential information, discussions fell apart in August of the same year. Shortly thereafter, RA Capital helped establish Avilar Therapeutics, which allegedly utilized the intellectual property obtained during these discussions to develop a competing therapeutic program, rather than seeking a legitimate partnership with Yale.

The ruling, delivered on July 24, 2026, found that Avilar and RA Capital acted willfully and maliciously in misappropriating the trade secrets. The jury awarded Yale $2 million for a breach of contract by RA Capital and $1 million each to both Yale and Biohaven for trade secret misappropriation, sending a strong message about the seriousness of respecting confidentiality agreements and protecting innovations.

"This verdict reaffirms our stance that RA Capital and Avilar misused confidential information to advance a rival company. We appreciate the jury's careful consideration and our team’s efforts in the trial," stated Dr. Vlad Coric, CEO of Biohaven. He emphasized the company's commitment to collaborating with esteemed institutions like Yale, aiming to drive the development of life-saving therapies.

In the aftermath of the verdict, Karen Peart, Yale's Associate Vice President for Communications, echoed the importance of protecting proprietary research. She noted that Dr. Spiegel’s work epitomizes decades of innovative scholarship at Yale and underlines the necessity of maintaining strong relationships between academic research and industry that are founded on trust and respect.

The case highlights broader implications for biotech companies and academia alike, as it underscores the vital role of legal frameworks in safeguarding trade secrets and fostering innovation through collaboration. Protecting intellectual property is essential not just for companies but also for governmental institutions and the public good, ensuring that extraordinary research translates into affordable, available treatments.

Biohaven and Yale were legally represented by KL Gates LLP and Morris James LLP, while Susman Godfrey LLP and Farnan LLP played roles for Yale. As the biotech industry continues to rapidly evolve, this verdict serves as a reminder of the importance of ethical conduct in business operations, particularly in fields where research and innovation are the cornerstones of success.

For Biohaven, the journey continues as they proceed with advancing the MODA platform, a testament to their ongoing collaboration with Yale, focusing on the development of effective treatments for patients combating debilitating diseases. As they move forward, stakeholders will be closely watching how this legal decision impacts the dynamics between biotech firms and academic institutions, especially concerning the confidentiality of shared research and technology.